Merck: Buy This Dividend Powerhouse While It's Cheap

Merck & Co. (MRK) is highlighted as an undervalued opportunity for long-term investors, trading near its 52-week low with a forward P/E of 9.1 and offering a 4.0% dividend yield. Despite a 2% year-over-year sales decline in Q2, primarily due to GARDASIL challenges in China, underlying sales grew 7%, driven by robust performance from Keytruda (up 9% YoY) and successful new launches like WINREVAIR, which generated over $1 billion in cumulative sales. The company maintains a strong balance sheet with an A+ credit rating and boasts a deep late-stage pipeline with over 80 Phase III studies and strategic acquisitions, positioning it for sustainable growth even as Keytruda's patent expiry in 2028 looms.

Analysis

Merck & Co. (MRK) appears to be trading at a significant valuation discount, with a forward P/E of 9.1, well below its historical average of 14.0, and a share price of $81 near its 52-week low. This valuation reflects market concerns over near-term headwinds, specifically a sharp decline in GARDASIL sales in China, which caused total Q2 2025 revenue to fall by 2% YoY to $15.8 billion. However, the company's underlying business demonstrates robust health, with sales growth of 7% when excluding the China-related impact. This strength is driven by the continued expansion of its flagship oncology drug, KEYTRUDA, which grew 9% YoY to $8.0 billion, and strong performance in its Animal Health division, up 11% YoY. Furthermore, new product launches are showing significant commercial traction; WINREVAIR generated $336 million in Q2 revenue, reaching over $1 billion in cumulative sales since its launch, while CAPVAXIVE added $129 million. The company's financial position is exceptionally strong, marked by an A+ credit rating, a low net debt-to-TTM EBITDA ratio of 0.95x, and an active capital return program, including a well-covered 4.0% dividend and $1.3 billion in Q2 share repurchases. While management's full-year revenue growth guidance of 1-2% is modest, the company's deep pipeline, with over 80 Phase III studies and strategic acquisitions like Verona Pharma, is positioned to address the primary long-term risk of Keytruda's patent expiry in 2028.

Key Decisions for Investors

• Given the stock is trading near its 52-week low with a forward P/E of 9.1, investors could consider the current price an attractive entry point for a long-term position, capitalizing on the market's apparent overemphasis on near-term headwinds.
• For income-oriented portfolios, the well-covered 4.0% dividend yield, backed by a 41% payout ratio and an A+ rated balance sheet, presents a compelling source of growing income.
• Investors should closely monitor the sales trajectory of new products like WINREVAIR and progress in the late-stage pipeline, as these are the key catalysts that must materialize to offset the eventual revenue impact from Keytruda's patent expiration in 2028.
• It is prudent to assess the investment with a long-term horizon, looking beyond the modest 1-2% full-year revenue guidance and focusing on the 7% underlying growth rate, strategic pipeline development, and potential for a valuation re-rating.